NAD+ Longevity: Biomarkers and Genetic Predispositions

Last reviewed: May 30, 2026

Last updated: May 30, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme essential for cellular energy metabolism, DNA repair, and stress response. NAD+ levels naturally decline with age, declining approximately 50% between ages 20 and 60, which may contribute to age-related metabolic changes.

For individuals interested in longevity optimization, understanding your baseline metabolic state and genetic predispositions can support more targeted discussions with healthcare providers. PlexusDx emphasizes precision-wellness approaches that align interventions with individual genetic and biomarker context.

NAD+ Biosynthesis and Cellular Function

NAD+ participates in over 500 enzymatic reactions, including energy production via the electron transport chain, NAD+-dependent deacetylases (sirtuins), and DNA damage repair pathways. These processes directly influence mitochondrial function, stress resilience, and tissue regeneration.

Cells synthesize NAD+ through two primary pathways: the de novo pathway from tryptophan and the salvage pathway from nicotinamide precursors. Age-related declines in NAD+ availability may impair these repair mechanisms, contributing to metabolic aging.

NAD+ Biomarkers and Personalized Assessment Framework

Baseline NAD+ measurement and related biomarkers—including NAD+/NADH ratios, sirtuin activity markers, and mitochondrial function indicators—can provide context for longevity planning. However, clinical NAD+ testing availability varies by provider and healthcare setting.

Biomarker or Assessment	Clinical Relevance
NAD+ serum or tissue levels	Direct measure of coenzyme availability; declines with age and metabolic stress
NAD+/NADH ratio	Reflects cellular redox state and mitochondrial efficiency; lower ratios suggest energy stress
Sirtuin activity markers (SIRT1, SIRT3)	NAD+-dependent enzymes governing metabolic regulation and stress response pathways
Mitochondrial ATP production capacity	Functional measure of energy metabolism dependent on intact NAD+-linked pathways

NAD+ Precursors and Interventions: Evidence Overview

Common NAD+ boosting strategies include nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), niacin, and tryptophan-derived pathways. Clinical evidence supports NAD+ precursor supplementation for NAD+ restoration in controlled settings, though individual response varies significantly.

Research in aging models demonstrates that elevated NAD+ levels support mitochondrial function and stress-response pathways. Human studies remain relatively limited; most longevity protocols combine NAD+ support with metabolic lifestyle interventions, making isolated NAD+ effects difficult to attribute.

Genetic Predispositions and Individual Variation in NAD+ Metabolism

Genetic variation in NAD+ synthesis and utilization pathways—including genes regulating tryptophan metabolism, niacin conversion, and sirtuin expression—may influence baseline NAD+ status and responsiveness to interventions. Individuals with certain genetic predispositions may experience greater metabolic drift with age.

Comprehensive genetic assessment in metabolic pathways can contextualize NAD+ planning within broader longevity strategy. PlexusDx Precision Peptide Genetic Test reveals predispositions in key metabolic regulatory genes, which should be interpreted with a qualified healthcare provider to support informed intervention selection.

Safety Considerations and Provider-Guided NAD+ Planning

NAD+ precursors are generally well-tolerated; common side effects include mild gastrointestinal effects and flushing. However, individuals with certain conditions—including active malignancies, uncontrolled diabetes, or renal dysfunction—should consult providers before initiating NAD+ protocols.

A qualified healthcare provider should evaluate your baseline metabolic state, medication interactions, and genetic context before recommending NAD+ interventions. Combining NAD+ support with evidence-based lifestyle modifications—sleep, exercise, stress management, nutritional optimization—is essential for sustained longevity benefits.

How PlexusDx Supports a More Personalized Approach

PlexusDx genetic assessment can provide context for understanding how your individual metabolic pathways may influence NAD+ status and longevity responsiveness. The Precision Peptide Genetic Test reveals predispositions in genes regulating energy metabolism, mitochondrial function, and stress-response pathways—information that may help provide context for personalized NAD+ and metabolic intervention planning.

The Precision Peptide Genetic Test examines variants in metabolic regulatory genes including those affecting nutrient utilization and cellular energy pathways. While genetic predispositions do not predict exact NAD+ precursor response, they can support a more informed conversation with your provider about which longevity interventions align with your individual metabolic profile.

Understanding your genetic predispositions in metabolic pathways enables more targeted discussions with healthcare providers about NAD+ supplementation, timing, dosing, and integration with peptide-based interventions or other longevity strategies. This precision-wellness approach optimizes resource allocation and supports better long-term adherence.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $179-$229/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the difference between NAD+ and NAD+ precursors like NMN or NR?

NAD+ is the active coenzyme in cells. NMN and NR are precursor molecules that cells convert to NAD+ via salvage pathways. Precursors are used therapeutically because direct NAD+ supplementation has poor bioavailability.

Can genetic testing predict how well NAD+ precursors will work for me?

Genetic predispositions in metabolic pathways can provide context for NAD+ metabolism, but they do not predict exact individual response. PlexusDx Precision Peptide Genetic Test should be interpreted with a qualified provider as part of comprehensive metabolic assessment.

How does NAD+ relate to GLP-1 peptide interventions?

Both NAD+ and GLP-1 pathways influence metabolic health and longevity signaling. Genetic predispositions in metabolic genes may inform decisions about combining NAD+ support with peptide-based interventions. PlexusDx can assess genetic context to support provider-guided integration.

At what age should I start NAD+ supplementation?

NAD+ decline begins in early adulthood but accelerates after age 50. The decision to supplement should be individualized based on baseline metabolic status, genetic factors, and provider assessment rather than age alone.

What biomarkers should I monitor while using NAD+ precursors?

NAD+/NADH ratio, mitochondrial function markers, metabolic hormones, and inflammatory markers are clinically relevant. Your provider should define a baseline assessment and monitoring schedule aligned with your personalized longevity plan and genetic predispositions.

NAD+ Longevity: Biomarker Context and Personalized Wellness Planning